Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.

about

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.

Item

http://www.wikidata.org/entity/Q36756034

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@ast

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@en

type

Item

label

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@ast

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@en

prefLabel

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@ast

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@en

P1476

Diagnostic and therapeutic upd ...... eated in a centre in one year.

@en

P2093

Abraham Hernandez

http://www.w3.org/2001/XMLSchema#string

Amparo Avaria

http://www.w3.org/2001/XMLSchema#string

Carmen Herrero-Vicent

http://www.w3.org/2001/XMLSchema#string

Carmen Illueca

http://www.w3.org/2001/XMLSchema#string

Claudia Salazar

http://www.w3.org/2001/XMLSchema#string

Isidro Machado

http://www.w3.org/2001/XMLSchema#string

Javier Lavernia

http://www.w3.org/2001/XMLSchema#string

Sergio Sandiego

http://www.w3.org/2001/XMLSchema#string

P2860

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Treatment of older patients with mantle-cell lymphoma.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

Molecular basis of mantle cell lymphoma.

P304

627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2016.627

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27110283

http://www.w3.org/2001/XMLSchema#string

P932

4817526

http://www.w3.org/2001/XMLSchema#string